Investing in data analytics and technology
As decision-making continues to become more data-driven, feasibility teams must continue to strengthen their analytics techniques. Our consortium shares tips to leverage RWD using artificial intelligence and machine learning to generate insights.
Benchmarking organizational processes
There is value in having local, boots-on-the-ground teams, even in the era of big data. We explore how our feasibility teams continue to evolve and recruit the right talent, while balancing new data with institutional knowledge.
As biopharma companies continue to grow, their feasibility teams must remain nimble. Our consortium discusses issues surrounding centralized governance, shared goals and visions, data sharing, sustainable improvement and more.
Cultivating patient-sponsor relationships
It is more important than ever to connect the head and the heart. This means always putting the concerns and benefits of the patient first. To achieve this, we aim to address patient-centric trial designs, effective engagement strategies and more.
Countries where our consortium member companies conduct trials
Projects completed every year
Funded by ZS, so our members pay no membership dues to participate in our consortium
Combined market cap of our consortium member companies
CLINICAL FEASIBILITY CONSORTIUM CHARTER
Life Sciences R&D & Medical
Using clinical trial sites’ input to select the right capabilities when decentralizing
March 21, 2023 | type:article
Life Sciences R&D and Medical
Towards data-driven clinical trial planning and strategy
Dec. 16, 2021 | type:article
AI & Analytics
Improving medication adherence through patient-centricity
Oct. 8, 2021 | type:article
Pharmaceuticals and Biotech
Amplifying patient voices in clinical trial protocol design
Sept. 7, 2021 | type:article